Compare Matson Inc (MATX) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Novo Nordisk A/S — how do they compare? Matson Inc trades at $225.53 (market cap $6.81B), while Novo Nordisk A/S trades at $38.62 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 24.3× Matson Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Novo Nordisk A/S for 116 Days on average.
| MATX | NVO | |
|---|---|---|
Market Cap | $6.81B | $165.31B |
Volume | 255,080 | 11,432,838 |
Sector | Industrials | Health |
52-Week High | $238.60 | $63.98 |
52-Week Low | $88.05 | $35.29 |
Typical Hold Time | 23 Days | 116 Days |
Enterprise Value | $7.41B | $179.56B |
Dividend Yield | 0.67% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $224.80, up 0.84% on the day, with a bullish technical signal from moving averages and a neutral stance from oscillators. The company reported strong Q2 2026 earnings of $4.27 per share, beating estimates, and raised its full-year outlook. Revenue growth is steady, with 2026 revenue projected at $3.5 billion and net profit at $464 million, supported by a robust net income margin of 13.41%.
The outlook for MATX is positive, driven by earnings beats, cost controls, and institutional accumulation. Key risks include exposure to freight demand cycles and competitive pressures. Wall Street consensus is bullish, with 8 of 12 analysts rating it a Buy and an implied 27.33% upside potential, though investors should monitor macroeconomic trends affecting transportation stocks.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
